论文部分内容阅读
应用ＡＰＡＡＰ桥联酶标法检测肺癌患者３０例和正常人１２例的Ｔ淋巴细胞亚群。肺癌组ＣＤ３＋为６７．４±５．６４％，ＣＤ４＋为３７．９±３．７２％，ＣＤ８＋为３２．８±３．１７％，ＣＤ４／ＣＤ８比值为１．１７±０．１４。正常组ＣＤ３＋为７５．２５±２．８％，ＣＤ４＋为４３．３±３．７％，ＣＤ８＋为３０．５±３．５％，ＣＤ４／ＣＤ８比值为１．４４±０．２３。肺癌组的ＣＤ３＋、ＣＤ４＋、ＣＤ４／ＣＤ８比值均明显低于正常对照组（Ｐ＜０．０１），而ＣＤ８＋则高于正常对照组（Ｐ＜０．０５），与一般文献报告一致。肿瘤病人外周血中Ｔ淋巴细胞亚群的数量及其分布异常，揭示肿瘤病人的细胞免疫功能处于免疫抑制状态，机体对识别和杀伤突变细胞的能力下降，导致肿瘤的生长和转移。因此，Ｔ细胞亚群的检测分析作为判断细胞免疫功能的一项重要指标，已日益受到重视。
The T-lymphocyte subsets were detected in 30 patients with lung cancer and 12 normal controls by APAAP bridging enzyme labeling method. In the lung cancer group, CD3+ was 67.4±5.64%, CD4+ was 37.9±3.72%, CD8+ was 32.8±3.17%, and CD4/CD8 ratio was 1.17±0.14. In the normal group, CD3+ was 75.25±2.8%, CD4+ was 43.3±3.7%, CD8+ was 30.5±3.5%, and CD4/CD8 ratio was 1.44±0.23. The ratios of CD3+, CD4+, and CD4/CD8 in the lung cancer group were significantly lower than those in the normal control group (P<0.01), while CD8+ was higher than that in the normal control group (P<0.05), which was consistent with the general literature reports. The abnormal number and distribution of T lymphocyte subsets in the peripheral blood of tumor patients reveal that the cellular immune function of cancer patients is in an immunosuppressed state, and the body’s ability to recognize and kill mutant cells declines, leading to tumor growth and metastasis. Therefore, the detection and analysis of T cell subsets has become an important indicator to determine the cellular immune function, and it has been increasingly valued.